Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Open-label, Phase I Dose Escalation and Expansion Cohort Study of EOS301984 as Monotherapy and in Combination With Other,Anticancer Treatments in Participants With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A First-in-Human Open-label, Phase I Dose Escalation and Expansion Cohort Study of EOS301984 as Monotherapy and in Combination With Other,Anticancer Treatments in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EOS-984 (Primary) ; Pembrolizumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors iTeos Therapeutics

    • Most Recent Events

    • 05 Mar 2025 According to an iTeos Therapeutics media release, the company has completed enrollment of second dose cohort of EOS-984 + pembrolizumab combination in ongoing Phase 1 trial.
    • 10 Jan 2025 According to an iTeos Therapeutics media release,data from the study anticipated in 2H25.
    • 06 Mar 2024 According to an iTeos Therapeutics media release, the company completed enrollment of the third dose cohort and continued advancement in the dose escalation of the Phase 1 trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top